Skip to main content

Table 3 Gene mutation features of 14 BCORMUT patients who accepted decitabine induction

From: Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome

Case no Class Cycles* Response BCOR mutations (VAF) Concomitant mutations
1 RAEB-t 2 CR BCOR/4/C925Y (51%) DHX9; WT1
2 RAEB1 6 CR BCOR/11/K1452X (60%) DNMT3A; ROBO1; STAG2
3 RAEB2 4 CR BCOR/8/R1323W (50%) NPM1
4 CMML1 3 CR BCOR/8/K1339N (33%) ASXL1; MPL; TET2; UPF3A
5 RAEB1 4 mCR + HI BCOR/4/A619fs (16%) PHF6; RUNX1; TET2
6 RCMD 3 CR BCOR/4/Y361fs (85%) NRAS; ROBO1; RUNX1; U2AF1
7 RCMD 4 CR BCOR/12/R1547*(49%) ASXL1; RUNX1; SRSF2
8 RAEB1 4 mCR BCOR/4/p819-819del (74%) DNMT3A; IDH2; ROBO1; RUNX1
9 RAEB2 4 CR BCOR/7/R1165X (29%)/11/C4326 + 1C > A (56%) CEBPA; DNMT3A; RUNX1; STAG2;TET2; U2AF1
10 RAEB2 4 NR BCOR/7/P1101fs (65%) ITIH3
11 RAEB2 4 CR BCOR/4/V912fs (32%) ASXL1; STAG2
12 RCMD 2 NR BCOR/4/P483L (48%) DHX9; EZH2; IDH1; U2AF1
13 RAEB2 4 mCR + HI BCOR/4/T738fs (46%) EZH2; MPL; RUNX1
14 CMML2 2 NR BCOR/4/P483L (100%) None
  1. *The induced decitabine cycles number means the course number of continuously accepted decitabine treatment (the durations between courses did not exceed 30 days); For the CR achieved patients with less than 4 induced courses. (No. 1, 4 and 6), the patients rejected continuously decitabine usage by themselves